CXCL12-CXCR4轴、CCL21-CCR7轴在非霍奇金淋巴瘤中的研究进展  

Research advances of CXCL12-CXCR4 axis and CCL21-CCR7 axis in non-Hodgkin's lymphoma

作　　者：卢莹莹 李文辉[1] LU Yingying;LI Wenhui(Department of Clinical Laboratory,Cancer Hospital Affiliated to Harbin Medical University,Heilongjiang Harbin 150000,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院检验科,黑龙江哈尔滨150000

出　　处：《现代肿瘤医学》2021年第15期2712-2716,共5页Journal of Modern Oncology

基　　金：University of Texas MD Anderson Cancer Center Sister Institution Network Fund Application。

摘　　要：非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)是由免疫系统中成熟和未成熟细胞的恶性转化所致,涉及B淋巴细胞(B细胞,约占所有NHL的86%)、较小比例的T细胞和自然杀伤(NK)细胞(在发展中地区约占14%)。近年来相关研究表明,趋化因子受体4(CXCR4)、趋化因子受体7(CCR7)在淋巴细胞归巢中发挥重要作用,且已被证实在多种实体及血液恶性肿瘤中高表达,通过与其相应的配体结合显示出促肿瘤发生、发展的多向性效应。针对CXCR4、CCR7靶向治疗应用的研究,尤其是CXCR4定向成像和放射性核素治疗领域的研究非常活跃,预计在未来几年内,转化医学方面将有新的发展。然而现就CXCR4、CCR7在NHL中作用的相关报道甚少。本文就CXCL12-CXCR4轴、CCL21-CCR7轴在NHL中的作用机制、预后意义及治疗应用等方面的研究进展作一综述。Non-Hodgkin's lymphoma is caused by malignant transformation of mature and immature cells in the immune system,in which B lymphocytes(B cells,approximately 86%of all NHL)and a small proportion of T cells and natural killer(NK)cells(approximately 14%in developing areas).In recent years,related studies have shown that chemokine receptor 4(CXCR4)and chemokine receptor 7(CCR7)play an important role in lymphocyte homing,and they have been proved to be highly expressed in a variety of solid and hematologic malignancy,showing a polytropic effect of promoting the occurrence and development of tumors by binding to their corresponding ligands.In addition,studies on the application of CXCR4 and CCR7 targeted therapy,especially in the fields of CXCR4 targeted imaging and CXCR4-directed endoradiotherapy,are very active.It is expected that there will be new developments in translational medicine in the next few years.However,there are few reports about the role of CXCR4 and CCR7 in NHL.This review summarizes the research progress of CXCL12-CXCR4 axis and CCL21-CCR7 axis in NHL mechanism,prognostic significance and therapeutic application.

关 键 词：非霍奇金淋巴瘤 趋化因子受体4 趋化因子受体7 肿瘤转移 

分 类 号：R733[医药卫生—肿瘤]